K
Katja Kiseljak-Vassiliades
Researcher at University of Colorado Denver
Publications - 38
Citations - 1114
Katja Kiseljak-Vassiliades is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Adrenocortical carcinoma & Pituitary tumors. The author has an hindex of 15, co-authored 32 publications receiving 875 citations. Previous affiliations of Katja Kiseljak-Vassiliades include Johns Hopkins University School of Medicine & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer.
Shuiying Hu,Dingxie Liu,Ralph P. Tufano,Kathryn A. Carson,Eli Rosenbaum,Yoram Cohen,Elizabeth H. Holt,Katja Kiseljak-Vassiliades,Kerry J. Rhoden,Sara M. Tolaney,Stephen Condouris,Giovanni Tallini,William H. Westra,Christopher B. Umbricht,Martha A. Zeiger,Joseph A. Califano,Vasily Vasko,Mingzhao Xing +17 more
TL;DR: The results suggest that aberrant methylation and hence silencing of TIMP3, SLC5A8, DAPK and RARβ2, in association with BRAF mutation, may be an important step in PTC tumorigenesis and progression.
Journal ArticleDOI
Gonadotropin-releasing hormone (GnRH) neuron migration: initiation, maintenance and cessation as critical steps to ensure normal reproductive function.
TL;DR: The current cadre of candidates thought to modulate GnRH neuronal migration are outlined and may shed new light on human reproductive disorders and provide potential targets to develop new pro-fertility or contraceptive agents.
Journal ArticleDOI
Identification of Growth Arrest and DNA-Damage-Inducible Gene β (GADD45β) as a Novel Tumor Suppressor in Pituitary Gonadotrope Tumors
Katherine A. Michaelis,Aaron J. Knox,Mei Xu,Mei Xu,Katja Kiseljak-Vassiliades,Katja Kiseljak-Vassiliades,Michael G. Edwards,Mark W. Geraci,Bette K. Kleinschmidt-DeMasters,Kevin O. Lillehei,Margaret E. Wierman,Margaret E. Wierman +11 more
TL;DR: GADD45β is a novel pituitary tumor suppressor whose reexpression blocks proliferation, survival, and tumorigenesis, and together these studies identify new targets and mechanisms to explore in pituitsary tumor initiation and progression.
Journal ArticleDOI
Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer.
Andrew Weickhardt,Micol S. Rothman,Smita Salian-Mehta,Katja Kiseljak-Vassiliades,Ana B. Oton,Robert C. Doebele,Margaret E. Wierman,Margaret E. Wierman,D. Ross Camidge +8 more
TL;DR: The objective of this study was to document the differences in testosterone (T) levels between crizotinib‐treated and noncrizotin ib‐treated patients with metastatic nonsmall cell lung cancer (NSCLC).
Journal ArticleDOI
Growth hormone tumor histological subtypes predict response to surgical and medical therapy.
Katja Kiseljak-Vassiliades,Katja Kiseljak-Vassiliades,Nichole E. Carlson,Manuel Thomas Borges,Bette K. Kleinschmidt-DeMasters,Kevin O. Lillehei,Janice M. Kerr,Margaret E. Wierman,Margaret E. Wierman +8 more
TL;DR: Clinical data were correlated with histologic subtype and disease control, as defined by IGF-1 levels, and random growth hormone levels in response to surgery and/or medical therapies and prognostic significance for surgical success and response to medical therapies.